Henry E. Schea
President bij Genopoietic SA
Profiel
Henry E.
Schea is currently the President & General Director at Genopoietic SA since 2009.
Prior to this, he worked at AVAX Technologies, Inc. as the Executive Director-Regulatory Affairs from 2011 to 2016.
He completed his undergraduate degree from the University of Massachusetts in 1976.
Actieve functies van Henry E. Schea
| Bedrijven | Functie | Begin |
|---|---|---|
Genopoietic SA
 Genopoietic SA BiotechnologyHealth Technology Part of AVAX Technologies, Inc., Genopoietic SA is a French company that researches and develops cell and gene therapy for cancer, autoimmune diseases, and orthopedics. The company is based in Paris, France. Genopoietic was acquired by AVAX Technologies, Inc. on August 24, 2000 for $198.62 million. | President | 21-10-2011 |
Eerdere bekende functies van Henry E. Schea
| Bedrijven | Functie | Einde |
|---|---|---|
| AVAX TECHNOLOGIES, INC. | Algemeen Adviseur | 01-04-2016 |
Opleiding van Henry E. Schea
| University of Massachusetts | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AVAX TECHNOLOGIES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Genopoietic SA
Genopoietic SA BiotechnologyHealth Technology Part of AVAX Technologies, Inc., Genopoietic SA is a French company that researches and develops cell and gene therapy for cancer, autoimmune diseases, and orthopedics. The company is based in Paris, France. Genopoietic was acquired by AVAX Technologies, Inc. on August 24, 2000 for $198.62 million. | Health Technology |
